Literature DB >> 30042636

Prediction of Conversion from Clinically Isolated Syndrome to Multiple Sclerosis According to Baseline Characteristics: A Prospective Study.

Bilge Piri Çinar1, Serkan Özakbaş2.   

Abstract

OBJECTIVE: Clinically isolated syndrome (CIS) is a clinical state that proceeds with inflammation and demyelination, suggestive of multiple sclerosis (MS) in the central nervous system in the absence of other alternative diagnoses. The purpose of this study was to determine in a prospective cohort, the predictor factors in conversion from CIS to MS on the basis of clinical, magnetic resonance (MR) imaging and cerebrospinal fluid (CSF) findings.
METHODS: Forty-one CIS patients were included in this study and followed up for at least two years.
RESULTS: Clinically, polysymptomatic or sensorial involvement, good prognostic factors and complete response to pulse therapy were found to be of prognostic value in conversion to MS. A greater presence of oligoclonal bands in CSF was identified in the converted group (92.8%). In terms of localization, presence of callosal lesion (71.4%), periventricular lesion (97.1%), Gd-enhanced lesion (48.6%), black hole (54.2%) and brainstem lesion (57.1%) was statistically significant in terms of conversion to MS.
CONCLUSION: A carefully performed neurological assessment of symptoms and signs, and evaluation of lesions on MR combined with CSF findings are important for identifying the risk of conversion to MS. This information may be useful when considering treatment in CIS patients instead of waiting for conversion to MS.

Entities:  

Keywords:  Clinically isolated syndrome; conversion; multiple sclerosis; prognosis

Year:  2018        PMID: 30042636      PMCID: PMC6045808          DOI: 10.29399/npa.12667

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  37 in total

1.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Authors:  L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

2.  Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR.

Authors:  J H van Waesberghe; M A van Walderveen; J A Castelijns; P Scheltens; G J Lycklama à Nijeholt; C H Polman; F Barkhof
Journal:  AJNR Am J Neuroradiol       Date:  1998-04       Impact factor: 3.825

3.  Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis.

Authors:  F Fazekas; H Offenbacher; S Fuchs; R Schmidt; K Niederkorn; S Horner; H Lechner
Journal:  Neurology       Date:  1988-12       Impact factor: 9.910

4.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

Authors:  L Truyen; J H van Waesberghe; M A van Walderveen; B W van Oosten; C H Polman; O R Hommes; H J Adèr; F Barkhof
Journal:  Neurology       Date:  1996-12       Impact factor: 9.910

5.  Acute transverse myelitis with normal brain MRI : long-term risk of MS.

Authors:  Jui Perumal; Rana Zabad; Christina Caon; Megan MacKenzie; Alexandros Tselis; Fen Bao; Zahid Latif; Imad Zak; Robert Lisak; Omar Khan
Journal:  J Neurol       Date:  2007-12-20       Impact factor: 4.849

Review 6.  Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management.

Authors:  David Miller; Frederik Barkhof; Xavier Montalban; Alan Thompson; Massimo Filippi
Journal:  Lancet Neurol       Date:  2005-06       Impact factor: 44.182

Review 7.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.

Authors:  David Miller; Frederik Barkhof; Xavier Montalban; Alan Thompson; Massimo Filippi
Journal:  Lancet Neurol       Date:  2005-05       Impact factor: 44.182

8.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

Authors:  L Kappos; C H Polman; M S Freedman; G Edan; H P Hartung; D H Miller; X Montalban; F Barkhof; L Bauer; P Jakobs; C Pohl; R Sandbrink
Journal:  Neurology       Date:  2006-08-16       Impact factor: 9.910

9.  Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI.

Authors:  P A Brex; K A Miszkiel; J I O'Riordan; G T Plant; I F Moseley; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-03       Impact factor: 10.154

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  3 in total

1.  Conversion of clinically isolated syndrome to multiple sclerosis: a prospective multi-center study in Eastern India.

Authors:  T K Banerjee; M Saha; E Ghosh; A Hazra; A Das; D Choudhury; S Ojha; A Haldar; A Mukherjee; S S Nandi; A Ghosh; A Mukherjee; A Chatterjee; A Datta; S Purakayastha
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-05-13

2.  Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis.

Authors:  Fay Probert; Tianrong Yeo; Yifan Zhou; Megan Sealey; Siddharth Arora; Jacqueline Palace; Timothy D W Claridge; Rainer Hillenbrand; Johanna Oechtering; David Leppert; Jens Kuhle; Daniel C Anthony
Journal:  Brain Commun       Date:  2021-04-19

Review 3.  Cerebellar and/or Brainstem Lesions Indicate Poor Prognosis in Multiple Sclerosis: A Systematic Review.

Authors:  Yuyuan Yang; Meng Wang; Lulu Xu; Meixiang Zhong; Yajuan Wang; Moxin Luan; Xingao Li; Xueping Zheng
Journal:  Front Neurol       Date:  2022-04-29       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.